4 most recent filings and news items mentioning EYPT. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/EYPT/news?limit=20"
Pull EYPT filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayEyePoint Inc. has completed enrollment for its pivotal DURAVYU trials for diabetic macular edema, achieved in just five months with 480 patients. Topline data is anticipated in 4Q 2027, followed by FDA and EMA review.
View filing at SEC.gov →EyePoint Inc. agreed to settle a lawsuit brought by the US government related to kickbacks for its drug DEXYCU. This legal resolution mitigates potential liability but signals significant regulatory scrutiny for the company.
View filing at SEC.gov →6 Health Care Stocks With Whale Alerts In Today’s Session
View filing at SEC.gov →EyePoint's board approved Amendment No. 3 to its 2023 Long-Term Incentive Plan, increasing the maximum shares available for equity awards to 15.3 million, pending stockholder approval. The expansion provides additional capacity for employee compensation and retention through equi
View filing at SEC.gov →